FLT3 and acute myeloid leukemia: Notably, the phase I clinical trial, which enrolled 21 patients, reported promising complete remission rates and a manageable toxicity profile in newly diagnosed (ND) FLT3-mutated AML patients treated with GO and midostaurin in combination with the 7 + 3 regimen (cytarabine and daunorubicin).